MiR-22-3p targeting alpha-enolase 1 regulates the proliferation of retinoblastoma cells - 11/07/18
, Huanhuan Li a, ⁎ , Yao Liu a, Zhichao Zhu bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 8 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
This study sought to explore the role of alpha-Enolase 1 (ENO1) in retinoblastoma (RB) which remains uncertain.
Methods |
The expression of ENO1 in RB cell lines was examined by RT-qPCR and western blot. The biological function of ENO1 on cell proliferation in RB was determined in vitro. The predicted target of ENO1 was validated by dual-luciferase reporter assay and rescue experiment. The validation of clinical tissue samples was performed by RT-qPCR.
Results |
Elevated ENO1 could promote the proliferation of RB cells. The dual luciferase reporter assay confirmed that ENO1 is the target for miR-22-3p. In rescue experiment, the result also indicated that miR-22-3p inhibits the proliferation of RB cells by negatively regulating the expression of ENO1. These differences were statistically significant (P<0.05).
Conclusion |
ENO1 functions as an oncogene in RB and inhibiting ENO1 by miR-22-3p suppresses the proliferation of RB cell lines. miR-22-3p/ENO1 pathway may serve as a novel target in RB.
Le texte complet de cet article est disponible en PDF.Keywords : ENO1, MiR-22-3p, Retinoblastoma, Proliferation
Plan
Vol 105
P. 805-812 - septembre 2018 Retour au numéro
Article précédent
- RETRACTED: Tripterine alleviates LPS-induced inflammatory injury by up-regulation of miR-146a in HaCaT cells
- Ying Xiong, Yanlong Yan, Yuzhu Li
- Incensole acetate prevents beta-amyloid-induced neurotoxicity in human olfactory bulb neural stem cells
- Mohammed A. El-Magd, Sara F. Khalifa, Faisal Abdulrahman A. Alzahrani, Abdelnaser A. Badawy, Eman S. El-Shetry, Lamess M. Dawood, Mohammed M. Alruwaili, Hedib A. Alrawaili, Engi F. Risha, Fathy M. El-Taweel, Hany E. Marei
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?